Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cameron Health starts ICD trial

This article was originally published in The Gray Sheet

Executive Summary

Firm begins a pivotal study March 18 to support FDA approval efforts for its subcutaneous implantable cardioverter defibrillator (S-ICD) system for patients at risk of sudden cardiac arrest. The device does not require leads in or near the heart. In addition, because components are positioned using anatomical landmarks, the S-ICD does not require imaging equipment to place the implant. FDA has granted an investigational device exemption for the study, which will enroll up to 330 subjects at up to 35 sites globally, including the U.S. New Zealand was among the first sites to test the S-ICD (1"The Gray Sheet" June 8, 2009)
Advertisement

Related Content

Financings In Brief
Research In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

MT028657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel